

Endometrial tissue ablation: a clinical trial

| | | |
|--|--|--|
| Submission date 12/09/2005 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered |
| Registration date 12/09/2005 | Overall study status Completed | <input type="checkbox"/> Protocol |
| Last Edited 27/10/2010 | Condition category Urological and Genital Diseases | <input type="checkbox"/> Statistical analysis plan |
| | | <input checked="" type="checkbox"/> Results |
| | | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr J. Kleijn

Contact details
Maxima Medisch Centrum
Locatie Veldhoven
P.O. Box 7777
Veldhoven
Netherlands
5500 MB
+31 (0)40 8888000
J.Kleijn@mmc.nl

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title

Study objectives

Demonstrate that the HydroThermAblation procedure is equally effective compared to the Novasure procedure in achieving patient satisfaction at twelve months post-treatment for menorrhagia secondary to DUB.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Dysfunctional uterine bleeding

Interventions

Hydrothermablator (HTA) System versus ablation with Novasure

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Patients satisfaction:

At each follow up visit/telephone call patients satisfaction was noted. Patients can express their level satisfaction by using - completely satisfied, satisfied, doubtful satisfied or not satisfied. It is also noted if any kind of reintervention is performed, such as the use of oral contraceptives or surgery.

Key secondary outcome(s)

1. Quality of life: all patients are asked to complete quality of life questionnaires at baseline, at two days, six weeks, three months, six months and twelve months after surgery. We evaluate quality of life with the medical outcomes study SF 36, the Rotterdam symptom checklist and a structured clinical history questionnaire.
2. Amenorrhoea: at each follow up visit/ telephone call duration of menstruation, dysmenorrhoea and presence of clots are registered. Patients also complete a pictorial chart.

Completion date

01/08/2007

Eligibility

Key inclusion criteria

1. Refractory menorrhagia with no definable organic cause (dysfunctional uterine bleeding).
2. Age over 25 years old
3. Uterine sound measurement of 6.0 - 12 cm (external os to internal fundus).
4. Failed, contraindicated or intolerance to conservative (medical) therapy.
5. Menstrual Diary:
A minimum PBLAC score of > 150 for 1 month. Intracavitary pathology, such as type 2 fibromas and small polyps (≤ 2 cm), confirmed by hysteroscopy or Saline Infused Sonography (SIS)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Not Specified

Key exclusion criteria

1. Presence of bacteremia, sepsis, or other active systemic infection
2. Active or recurrent chronic pelvic inflammatory disease
3. Patients with documented coagulopathies
4. Symptomatic endometriosis
5. Prior uterine surgery (except low segment cesarean section) which interrupts the integrity of the uterine wall e.g.transmural myomectomy or classical cesarean section. Prior endometrial ablations.
6. Patients on medications that could thin the myometrial muscle, such as long-term steroid use.
7. Patients on anticoagulants.
8. Desire to have children or to preserve fertility
9. Patients currently on hormonal birth control therapy or unwilling to use a non-hormonal birth control post-ablation.
10. Abnormal/Obstructed Cavity as confirmed by hysteroscopy, Saline Infused Sonography (SIS) or HSG. Specifically: Septate or bicornuate uterus or other congenital malformation of the uterine cavity.

Date of first enrolment

01/03/2005

Date of final enrolment

01/08/2007

Locations

Countries of recruitment

Netherlands

Study participating centre
Maxima Medisch Centrum
Veldhoven
Netherlands
5500 MB

Sponsor information

Organisation
Maxima Medisch Centrum (The Netherlands)

ROR
<https://ror.org/02x6rcb77>

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
Máxima Medisch Centrum (Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| Results article | results | 01/10/2010 | | Yes | No |